Beta Launch Saturday, 15 December 2018
Global Dow 3.79
2,835.68 0.13%
27 August 08:59 PM
S&P 500 4.08
2,443.05 0.17%
25 August 05:03 PM
EGX 23.25
12,949.65 0.18%
27 August 12:00 AM
TDWL -20.48
7,225.18 -0.28%
27 August 12:00 AM
DFM -21.94
3,602.55 -0.61%
27 August 12:00 AM
ADX -13.82
4,479.99 -0.31%
27 August 12:00 AM

EIB backs companies developing new cancer treatments

Companies developing new cancer treatments have a hard time raising the money to carry out their research, so the European Investment Bank finances them.

“These innovative companies often spend half their time trying to find the capital they need,” says Yu Zhang, head of the innovation finance unit at the European Investment Bank. “Rare diseases markets are not attractive for most investors, because they do not appear as profitable as other markets.”

“But we see the worth of these research projects,” he says, “and the impact they could have worldwide.”

That’s why the EIB loaned EUR 25 million to Apeiron Biologics, a private clinical stage biotech Austrian company, supporting their financial stability. Apeiron has been working in the field of immune-oncology and it is one of a number of innovative companies financed by the EIB to develop new cancer treatments. It’s vital work, because cancer cases are predicted to increase by 68% by 2030. “This will help us achieve the next level of our development,” says Peter Llewellyn-Davies, Apeiron’s chief financial officer.

Apeiron already achieved great success in bringing their new treatment for pediatric neuroblastoma to the European market in 2017.

“To develop the innovative projects we currently have in our pipeline, we need sufficient financing,” says Llewellyn-Davies.

Apeiron is currently pursuing two main approaches. First, an antibody-based approach. Therapeutic antibodies selectively bind to tumor cells which express a certain “signal”, a glycolipid GD2 on their surface. This way, the tumor cells can be destroyed by the patient’s immune system. Apeiron’s second approach is a unique, novel cellular therapy currently under clinical development. Patient’s own blood cells are “re-programmed” through inhibition of a negative regulator of the immune system (cbl-b protein). They are then reinfused into the patient and help to combat the tumor.

 “We want to provide patients with effective treatments but less side effects,” says Llewellyn-Davies. “We do so by helping the immune system become reactivated and responsive to tumor cells present in the body, thus helping kill the tumor from within using our novel individual cellular immunotherapy.

RECOMMENDED

COMMENTS

There are no comments yet

LEAVE A COMMENT

Share with

My Account

Forgot password?

Create An Account

Forgot password?

Restore password

Subscribe to read
Already subscribed? Click here

For a limited time!
12 Months = 15 Months
24 Months = 32 Months
(Included Postal Fees worldwide)

Read, Explore Opportunities
Be connected with Business, Investment, Finance, Stock Exchange, Currencies, Development and International Cooperation

3 Months

18 USD / 60 AED

English Edition

Subscribe

3 Months

18 USD / 60 AED

Arabic Edition

Subscribe

3 Months

29.9 USD / 99 AED

Both Editions

Subscribe

6 Months

36 USD / 120 AED

English Edition

Subscribe

6 Months

36 USD / 120 AED

Arabic Edition

Subscribe

6 Months

59.9 USD / 199 AED

Both Editions

Subscribe

12 Months

72 USD / 240 AED

English Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

72 USD / 240 AED

Arabic Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

122 USD / 408 AED

Both Editions
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

24 Months

144 USD / 480 AED

English Edition
Amazing Deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

144 USD / 480 AED

Arabic Edition
Amazing deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

240 USD / 799 AED

Both Editions
Amazing deal!
(32 Months instead of 24 Months)

Subscribe
* Terms and conditions apply.